STEPHEN HENRY FRIEND
Medical Practice in Philadelphia, PA
License number
Pennsylvania MD028591E
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Philadelphia, PA 19106
Personal information
See more information about STEPHEN HENRY FRIEND at radaris.comName
Address
Phone
43 Langstoon Ln, Media, PA 19063
1322 Butternut Dr, Southampton, PA 18966
1550 Deal Rd, Meyersdale, PA 15552
101 Mermaid Ln, Philadelphia, PA 19118
1322 Butternut Dr, Southampton, PA 18966
Professional information
See more information about STEPHEN HENRY FRIEND at trustoria.com
Classification Of Breast Cancer Patients Using A Combination Of Clinical Criteria And Informative Genesets
Classification Of Breast Cancer Patients Using A Combination Of Clinical Criteria And Informative Genesets
US Patent:
8019552, Sep 13, 2011
Filed:
Mar 7, 2005
Appl. No.:
10/591800
Inventors:
Hongyue Dai - Kenmore WA, US
Laura J. Van't Veer - Amsterdam, NL
John Lamb - Shoreline WA, US
Roland Stoughton - San Diego CA, US
Stephen H. Friend - Philadelphia PA, US
Yudong He - Kirkland WA, US
Laura J. Van't Veer - Amsterdam, NL
John Lamb - Shoreline WA, US
Roland Stoughton - San Diego CA, US
Stephen H. Friend - Philadelphia PA, US
Yudong He - Kirkland WA, US
Assignee:
The Netherlands Cancer Institute - Amsterdam
Merck Sharp & Dohme Corp. - Rahway NJ
Merck Sharp & Dohme Corp. - Rahway NJ
International Classification:
G01N 33/48, G01N 33/50
US Classification:
702 19, 703 2, 435 6, 435 71, 436 64, 436 86, 436 94
Abstract:
The present invention provides prognostic methods for conditions such as cancer, for example, breast cancer, comprising classifying an individual by a plurality of phenotypic, genotypic or clinical characteristics of the condition into a plurality of patient subsets, and analyzing the pattern of expression of prognosis-informative genes identified for that subset in a sample from the individual. The present invention also provides methods for constructing such patient subsets and of identifying prognosis-informative genesets for such subsets. The invention further provides methods of assigning a therapeutic regimen to an individual, microarrays useful for performing prognosis, kits comprising these microarrays, and computer systems and programs for implementing the methods of the invention.
Methods Of Characterizing Drug Activities Using Consensus Profiles
Methods Of Characterizing Drug Activities Using Consensus Profiles
US Patent:
6801859, Oct 5, 2004
Filed:
Dec 23, 1998
Appl. No.:
09/220142
Inventors:
Stephen H. Friend - Philadelphia PA
Roland Stoughton - San Diego CA
Yudong He - Kirkland WA
Roland Stoughton - San Diego CA
Yudong He - Kirkland WA
Assignee:
Rosetta Inpharmatics LLC - Seattle WA
International Classification:
G01N 3348
US Classification:
702 19, 435 6, 435 71, 435 72, 435 691, 703 11
Abstract:
The present invention provides methods for enhanced detection of biological response profiles. In particular, the methods of this invention allow for the detection of biological response patterns, such as gene expression patterns, in response to different drug treatments. The methods of the invention also allow the determination of a âconsensus profileâ which describes a particular class or type of biological response. In certain embodiments the consensus profile may describe the biological response of a particular group or class of drugs. In other embodiments, the consensus profile may describe an âidealâ biological response such as one associated with a desired therapeutic effect. The methods of the present invention also allow for the comparison of different biological responses. Thus, the methods of the invention may be used, e. g.
Iterative Probe Design And Detailed Expression Profiling With Flexible In-Situ Synthesis Arrays
Iterative Probe Design And Detailed Expression Profiling With Flexible In-Situ Synthesis Arrays
US Patent:
7013221, Mar 14, 2006
Filed:
Apr 28, 2000
Appl. No.:
09/561487
Inventors:
Stephen H. Friend - Philadelphia PA, US
Roland Stoughton - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Julja Burchard - Marysville WA, US
Roland Stoughton - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Julja Burchard - Marysville WA, US
Assignee:
Rosetta Inpharmatics LLC - Seattle WA
International Classification:
G01N 33/48, C12Q 1/68
US Classification:
702 20, 702 19, 435 6
Abstract:
Methods and compositions are provided that are useful for detecting and reporting a plurality of different target polynucleotide sequences in a sample, such as polynucleotides corresponding to a plurality of different genes expressed by a cell or cells. In particular, the invention provides methods for screening a plurality of candidate polynucleotide probes to evaluate both the sensitivity and the specificity with which each candidate probe hybridizes to a target polynucleoide sequence. Candidate polynucleotide probes can then be ranked according to both their sensitivity and specificity, and probes that have optimal sensitivity and specificity for a target polynucleotide sequence can be selected. In one embodiment, polynucleotide probes can be selected according to the methods described herein to prepare “screening chips” wherein a large number of target polynucleotide sequences are detected using a single microarray have a few (e. g. , 1–5) probes for each target polynucleotide sequence.
Methods For Removing Artifact From Biological Profiles
Methods For Removing Artifact From Biological Profiles
US Patent:
6950752, Sep 27, 2005
Filed:
Dec 23, 1998
Appl. No.:
09/220275
Inventors:
Stephen H. Friend - Philadelphia PA, US
Roland Stoughton - San Diego CA, US
Yudong He - Kirkland WA, US
Roland Stoughton - San Diego CA, US
Yudong He - Kirkland WA, US
Assignee:
Rosetta Inpharmatics LLC - Seattle WA
International Classification:
G01N033/48, C12Q001/68, C12P021/06, G06G007/48
US Classification:
702 19, 435 6, 435 691, 703 11
Abstract:
The invention provides methods for removing unwanted response components (i. e. , “artifacts”) from a measured biological profile comprising measurements of a plurality of cellular constituents of a cell or organism in response to a perturbation. The methods involve subtracting from the measured biological profile one or more artifact patterns, each of which comprises measurements of changes in cellular constituents as a result of deviation of one or more experimental variables, such as cell culture density and temperature, hybridization temperature, as well as concentrations of total RNA and/or hybridization reagents, from desired values.
Synthetic Lethal Screen Using Rna Interference
Synthetic Lethal Screen Using Rna Interference
US Patent:
2005018, Aug 18, 2005
Filed:
Sep 22, 2004
Appl. No.:
10/947637
Inventors:
Peter Linsley - Seattle WA, US
Mao Mao - Redmond WA, US
Annette Kim - Harleysville PA, US
Stephen Friend - Philadelphia PA, US
Steven Bartz - Seattle WA, US
Michele Cleary - Bothell WA, US
Mao Mao - Redmond WA, US
Annette Kim - Harleysville PA, US
Stephen Friend - Philadelphia PA, US
Steven Bartz - Seattle WA, US
Michele Cleary - Bothell WA, US
International Classification:
C12Q001/68, C07H021/02, C12N015/85
US Classification:
435006000, 435455000, 536023100
Abstract:
The invention provides a method for identifying one or more genes in a cell of a cell type which interact with, e.g., modulate the effect of, an agent, e.g., a drug. For example, an identified gene may confer resistance or sensitivity to a drug, i.e., reduces or enhances the effect of the drug. The invention also provides STK6 and TPX2 as a gene that exhibits synthetic lethal interactions with KSP encoding a kinesin-like motor protein, and methods and compositions for treatment of diseases, e.g., cancers, by modulating the expression of STK6 or TPX2 gene and/or the activity of STK6 or TPX2 gene product. The invention also provides genes involved in cellular response to DNA damage, and their therapeutic uses.